The WSIB is seeking applications for a new funding competition. The WSIB Grants Program will be awarding one successful application for a systematic review of the scientific evidence for a causal association between occupational exposure to allergens and irritants and the development of occupational asthma.

Outcomes from the systematic review may be considered by the WSIB to determine whether the scientific evidence meets the recommended standards for scheduling, policy development or to underpin adjudicative support in case-by-case decision-making.

The review must address:

• ·         occupations of concern (e.g., auto industry workers (i.e., manufacturing and repair), food industry workers (i.e., bakers, seafood workers), painters, welders and metal forming workers, agricultural workers, wood workers, health care workers, cleaners and janitorial workers, printing industry), and
• ·         occupational exposures (i.e., allergens or irritants) of concern (e.g., isocyanates, metal dust and fumes, flour dust, wood dust, molds, aldehydes, acrylates, metal working fluids, cleaning agents, paints, solvents, fumes, adhesives/epoxy/glues, allergenic non-offset sprays in the printing industry)

For more information about the strategic initiative and the application process, please visit our website.To express interest and obtain an application form, please email grants@wsib.on.ca.

The FY22 Defense Appropriations Act is anticipated to provide funding for the Chronic Pain Management Research Program (CPMRP) to support and promote innovative, high-impact research to prevent the development and improve the management of chronic pain, with specific emphasis on the utilization and implementation of non-opioid therapies or non-addictive complementary methods.  Per the FY19 CPMRP congressional appropriation, chronic pain is defined as a pain that occurs on at least half the days for 6 months or more, and which can be caused by issues including, but not limited to:  combat- and training-related physical or mental stress and trauma, migraines and chronic headaches, traumatic brain injury, arthritis, muscular-skeletal conditions, neurological disease, tick and vector-borne disease, other insect-transmitted or tropical disease, and cancer.  The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY22 CPMRP funding opportunity announcements for the following award mechanisms is posted on the Grants.gov website. 

Applications submitted to the FY22 CPMRP must address one or more of the following focus areas:

• Clinical Exploration Award

o   Chronification of pain

o   Effectiveness or observational studies of novel treatments or untested techniques/approaches/pathways to chronic pain management

• Investigator-Initiated Research Award

o   Chronification of pain

o   Development of non-opioid therapies and methods for the treatment of chronic pain

o   Effectiveness or observational studies of novel treatments or untested techniques/approaches/pathways to chronic pain management

• Translational Research Award

o   Comparative effectiveness studies (for evidence-based, efficacious interventions to manage or prevent chronic pain)

o   Implementation science (for evidence-based, efficacious interventions to manage or prevent chronic pain)

o   Observational studies related to chronic pain

Funding Opportunities-FY22 Chronic Pain Management Research Program, Congressionally Directed Medical Research Programs (CDMRP) (army.mil)

Clinical Exploration Award – Preproposal due July 12, 2022

Independent investigators at all levels

• ·      Supports proof-of-principle pilot studies, clinical trials, and correlative studies with the potential to resolve current clinical barriers.
• ·      Research must address one or both of the FY22 CPMRP CEA Focus Areas of chronification of pain and effectiveness or observational studies of novel or untested techniques/approaches/pathways to chronic pain management.
• ·      Explorative studies, innovative approaches, and stakeholder engagement are encouraged.
• ·      Preliminary data are not required.
• ·      Statistically underpowered studies of efficacy are not pilot studies and will not be supported under the FY22 CPMRP CEA mechanism.
• ·      Pre-application submission is required; application submission is by invitation only.
• ·      The maximum allowable funding for the entire period of performance is $250,000 for direct costs.
• ·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·      The maximum period of performance is 2 years.

Investigator-Initiated Research Award – Preproposal due July 12, 2022

Investigators at or above the level of Assistant Professor (or equivalent)

• ·      Supports innovative research that will make an original and important contribution to the field of research, patient care, and/or quality of life.
• ·      Research must address one of more of the FY22 CPMRP IIRA Focus Areas of chronification of pain, effectiveness or observational studies of novel or untested techniques/approaches/pathways to chronic pain management, or development of non-opioid therapies and methods of treatment of chronic pain.
• ·      Partnering Principal Investigator (PI) Option is available.
• ·      Multidisciplinary collaborations, innovative approaches, and stakeholder engagement are encouraged.
• ·      Clinical trials will not be funded.
• ·      Pre-application submission is required; application submission is by invitation only.
• ·      The maximum allowable funding for the entire period of performance is $900,000 for direct costs.
• ·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·      The maximum period of performance is 4 years.

Translational Research Award – Preproposal due July 12, 2022

Investigators at or above the level of Assistant Professor (or equivalent)

• ·      Supports translational research that will accelerate the movement of efficacious, evidence-based ideas into clinical applications.
• ·      Research must address one or more of the FY22 CPMRP TRA Focus Areas of implementation science, comparative effectiveness, or observational studies related to chronic pain.
• ·      Incorporation of stakeholder engagement is required.
• ·      Biopsychosocial models of assessment are encouraged.
• ·      Partnering PI Option is available.
• ·      Studies seeking to evaluate new therapies or approaches, either pharmacological or non-pharmacological, that have not been previously evaluated in a clinical setting will not be funded.
• ·      Pre-application submission is required; application submission is by invitation only
• ·      The maximum allowable funding for the entire period of performance is $1,400,000 for direct costs.
• ·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·      The maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements that are available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the CPMRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBRap.org

For more information, please contact Jill Sherman, International Research Faciliator, at intl.research@lakeheadu.ca.

The FY22 MBRP funding opportunity announcements for the following award mechanisms are posted on the Grants.gov website.

Applications submitted to the FY22 MBRP must address one or more of the following Focus Areas:

• Atypical Burns:  Development and/or validation of methods to prevent, triage, and/or treat burns resulting from exposure to cold, radiation, directed energy weapons, or high-voltage/combat-related electrical injuries.  Novel interventions that move beyond topical agents or dressings are of particular interest.
• Burn Injury During Mass Casualty:  Solutions to improve the triage, delivery, or capacity of care after burn mass casualty events
• Burn injury related complications:  Development and/or validation of methods to prevent, assess, and/or treat burn injury-related complications, including:

○       Over/under fluid resuscitation to include limited or low volume resuscitation

○       Acute respiratory distress syndrome (ARDS)

○       Sepsis

○       Inhalation injuries

https://cdmrp.army.mil/funding/mbrp

Clinical Translational Research Award – Preproposal due June 27, 2022

Investigators at all academic levels (or equivalent)

• ·  Intended to support human research projects that are likely to have a major impact on patient care by applying promising and well-founded research findings to the care of the burn-injured patient, particularly at the point of injury, or during the acute phase of injury.
• ·  Impact is a key component of this award mechanism and should be clearly described.
• ·  The proposed study must include clinical research, and may include initial proof-of-concept trials, studies involving use of human anatomical substances, observational studies, and/or involve some retrospective data analysis.
• ·  Large randomized clinical trials are discouraged.
• ·  Preliminary data is required.
• ·  Animal research is not allowed.
• ·  Pre-application submission is required; application submission is by invitation only.
• ·  The maximum allowable funding for the entire period of performance is $2.21 million for total costs (direct plus indirect costs)
• ·  Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·  The maximum period of performance is 4 years.

Technology/Therapeutic Development Award – Preproposal due June 27, 2022

Investigators at all academic levels (or equivalent)

• ·  Intended to support the translation of promising preclinical findings into products for clinical applications.
• ·  Product-oriented (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
• ·  Proof of concept demonstrating the potential utility of the proposed product, or a prototype/preliminary version of the proposed product, should already be established. 
• ·  Preliminary data is required.
• ·  Clinical trials are not allowed.
• ·  Pre-application submission is required; application submission is by invitation only.
• ·  The maximum allowable funding for the entire period of performance is $2.21 million for total costs (direct plus indirect costs)
• ·  Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·  The maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the MBRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

For more information, please contact Jill Sherman, International Research Facilitator, at intl.research@lakeheadu.ca.

The Canadian Glycomics Network (GlycoNet) is a Network of Centres of Excellence that focuses on the role of glycans in health. Areas of focus for GlycoNet in Cycle II (2020–2024) are cancer, chronic diseases, infectious diseases, and neurodegenerative diseases.

GlycoNet funds projects along the following research innovation continuum: translational research and development, clinical engagement, technology development, and knowledge and technology exchange and exploitation (KTEE).

Our Funding Programs

Clinical Partnerships

These grants offer funding opportunities for clinicians to validate glycomics data from clinical studies. Maximum request: $50,000 for one year. Download PDF Request For Proposals >>

Translational Grants

These grants further advance/translate projects with proof of concept and protected IP. Maximum request: $150,000 for one year, 1:1 matching required. Download PDF Request For Proposals >>

Strategic Initiatives

These grants fund partner-led initiatives to advance a partner challenge. Maximum request: $150,000 for one year, with possibility of one year renewal, 1:1 matching required. Download PDF Request for Proposals >>

International Partnerships

GlycoNet has formalized a partnership with Academia Sinica to co-fund collaborative research between two entities. These grants fund projects that involve at least two groups, one in Canada and one in Taiwan. GlycoNet will fund research conducted in Canada, while Academia Sinica will fund research conducted in Taiwan. Projects require at least a 1:1 matching and must be completed within 12 months. Download PDF Request for Proposals >> 

The specific objectives of this funding opportunity are:

• To generate knowledge regarding the heterogeneity of type 1 diabetes (T1D) that will enable and inform new precision medicine approaches for the prediction, prevention, care or treatment of T1D; and
• To advance curative and disease-modifying therapies for T1D using precision medicine approaches.

The objective of this current funding opportunity is to support 1-2 emerging, community-based projects that have a focus on improving health behaviours associated with risk/protective factors that may help to prevent and/or delay the onset and progression of dementia among project participants. Applicants are encouraged to focus on higher risk older subpopulations (55+), particularly those with co-occurring modifiable risk factors.

The purpose of this funding program is to support research projects that seek to advance cancer-related health equity. Projects must be collaborative, co-created by people both affected by cancer and by structural marginalization, and designed to address the systemic, structural, and institutional factors that sustain health disparities in Canada. Applications should take a social determinants of health perspective in identifying and defining both the health equity need and the community of focus, taking care to consider the intersectionalities of such communities.

The Canadian Cancer Society and the Canadian Institutes of Health Research – Institute of Cancer Research (ICR) are excited to announce the launch of a new funding opportunity. The intent of the CCS Breakthrough Team Grants: Transforming Low Survival Cancers is to bring together the sharpest minds and research talent from across Canada and beyond. By combining scientific, clinical, and patient expertise, in a collaborative, interdisciplinary environment and integrating the power of new technologies and interventions, we hope to find new ways to prevent the onset of, improve survival through early detection when the disease is at its most treatable, including the early detection of recurrence and metastatic spread, and develop more precise and effective treatments with fewer harmful side effects for the following six cancers:  

• ·       pancreas
• ·       esophagus
• ·       brain
• ·       lung
• ·       liver
• ·       stomach

Overview

Ontario Genomics is pleased to announce Genome Canada’s new Climate Action Genomics Initiative – Climate-Smart Agriculture and Food Systems funding opportunity, launched in May 2022. Interdisciplinary Challenge Teams (ICTs) represent the largest, key component of the initiative. ICTs are integrated teams of researchers from different disciplines and users who work together to address specific questions, achieve relevant deliverables and, ultimately, reduce the carbon footprint and greenhouse gas emissions of Canada’s agriculture and food systems. As part of the Initiative portfolio, the teams will work toward broader national impacts that manifest value beyond each individual project. The ICTs will provide genomic solutions to help implement agriculture and food production systems that are climate-resilient, socially responsible, economically viable and environmentally sustainable, and that contribute to the mitigation of climate change impacts.

Objectives

The ICT funding opportunity aims to support teams that use genomic approaches to achieve the overall objective of the Initiative, which is to develop and apply genomic tools and technologies to reduce greenhouse gas emissions and mitigate the carbon footprint of Canada’s food systems to ensure they are resilient, economically viable and environmentally sustainable.

The scope of this funding opportunity will include areas where genomic technologies are used to help achieve net-zero emissions by 2050 and reduce the carbon footprint of Canada’s agriculture and food production system. Projects should seek solutions that will increase the value created by production systems without increasing greenhouse gas emissions or amplifying negative impacts on the natural environment. Furthermore, projects should demonstrate how their outputs could be translated into reduced emissions by taking into account the various dimensions of the food system value chain, including production, processing, distribution and consumption.

Applicants must demonstrate how their proposal has significant potential to achieve concrete deliverables by the end of the funding period. Proposals that make a strong case that their deliverables will translate into significant social and/or economic benefits that align with the Initiative’s overall intended impact (i.e., the reduction of greenhouse gas emissions to lessen the carbon footprint of Canada’s agriculture and food production systems) within the shortest time frame possible after the end of the project are particularly encouraged. Consideration will be given to what is reasonable for different research areas.

The FY22 LRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. 

Applications submitted to the FY22 LRP Idea and Impact Awards must address one or more of the following Focus Areas:

• Understanding how lupus disease heterogeneity impacts risk of disease, disease presentation, clinical course, and outcomes; using a diverse range of research disciplines including, but not limited to, biopsychosocial studies, personalized medicine, variation in treatment studies, health economics, socioeconomic studies, environmental studies, and epidemiological studies
• Understanding the biological mechanisms of lupus disease including, but not limited to, studies of informative/rare patients
• Determining the pathobiology of end organ injury related to lupus disease in target human tissues
• Improving quality of life for individuals living with lupus including, but not limited to, addressing social determinants of health, access to healthcare resources, outcomes research, patient-reported outcomes, symptom and disease control, comparative effectiveness research, and issues and challenges that, when addressed, make day-to-day living with lupus easier and life more fulfilling
• Understanding the underlying genetic and epigenetic components and gene-environment interactions of lupus and how they may relate to clinical disease characteristics, variations, disparities and differences in response to therapies using functional genomic studies
• Innovative health care delivery models improving outcomes for lupus (Impact Award only)

Applications submitted to the FY22 LRP Transformative Vision Award must address one of the following Focus Areas:

• Innovative health care delivery models improving outcomes for lupus
• Design and implement an intervention either at the individual and/or healthcare system level to improve the quality of life for individuals living with lupus.  Example interventions include, but are not limited to, access to healthcare resources, outcomes research, symptom and disease control, comparative effectiveness research, and issues and challenges that, when addressed, make day-to-day living with lupus easier and life more fulfilling

Funding Opportunities-FY22 LRP, Congressionally Directed Medical Research Programs (CDMRP) (army.mil)

Idea Award – Letter of Intent due August 16, 2022

All investigators at or above the level of postdoctoral fellow (or equivalent)

• ·    Supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement relevant to lupus.
• ·    Emphasis on innovation.
• ·    Must address one of the Fiscal Year 2022 (FY22) LRP IA Focus Areas.
• ·    Clinical trials are not allowed.
• ·    Preliminary data are not required.
• ·    The maximum allowable funding for the entire period of performance is $300,000 for total costs (direct plus indirect costs).
• ·    The maximum period of performance is 2 years.

Impact Award – Letter of Intent due August 16, 2022

Independent investigators at or above the level of Assistant Professor (or equivalent)

• ·    Supports high-risk/high-reward research which, if successfully addressed, has the potential to make a major impact in lupus research.
• ·    Emphasis on impact.
• ·    Must address one of the FY22 LRP IPA Focus Areas.
• ·    Clinical trials are not allowed.
• ·    Preliminary data are encouraged but not required.
• ·    The maximum allowable funding for the entire period of performance is $750,000 for total costs (direct plus indirect costs).
• ·    The maximum period of performance is 4 years.

Transformative Vision Award – Letter of Intent due August 16, 2022

Independent investigators at or above the level of Assistant Professor (or equivalent)

• ·    Supports research that will have an intervention at the individual and/or healthcare system level, which will result in near-term impact on the health-related quality of life of persons living with lupus.
• ·    Emphasis on near-term impact to quality of life.
• ·    Must address the FY22 LRP TVA Focus Areas.
• ·    Human subject research and clinical trials are allowed.
• ·    Preliminary data are required.
• ·    Animal studies are not allowed.
• ·    Partnering Principal Investigator (PI) Option allows one Initiating Investigator and a maximum of two Partnering PIs.
• ·    The research team must include one or more Consumer Advocate(s).
• ·    The maximum allowable funding for the entire period of performance is $2.5 million for total costs (direct plus indirect).
• ·    The maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507

help@eBrap.org

For more information, please contact Jill Sherman, International Research Facilitator, at intl.research@lakeheadu.ca .